

## Anti-CCR4/CD194 Antibody (Mogamulizumab)

### Introduction

Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells through antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancer, adult T-cell leukemia/lymphoma (ATLL), and cutaneous T-cell lymphoma (CTCL).

### Product parameters

Alternative Names	Poteligeo, KW-0761
Target Accession	P51679
Target	CCR4 / CD194
CAS number	1159266-37-1
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human, Mouse
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

